BlackRock Group’s Tempest Therapeutics TPST Stock Holding History

BlackRock Group’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$14K	Hold	3	–	–	﹤0.01%	2964
2016 Q3	$62K	Sell	3 -5	-63%	-$90.5K	﹤0.01%	2887
2016 Q2	$117K	Hold	8	–	–	﹤0.01%	2745
2016 Q1	$216K	Buy	8 +6	+300%	+$127K	﹤0.01%	2551
2015 Q4	$44K	Hold	2	–	–	﹤0.01%	2842
2015 Q3	$40K	Buy	2 +1	+100%	+$67.3K	﹤0.01%	2883
2015 Q2	$104K	Buy	+1	New	+$91.6K	﹤0.01%	2737
2013 Q4	–	Sell	-1	Closed	-$31K	–	2775
2013 Q3	$31K	Buy	+1	New	+$35.5K	﹤0.01%	2776

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Group's TPST Position: Q4 2016 in Review

BlackRock Group held its Tempest Therapeutics (TPST) position steady in Q4 2016 at 3 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #2964.

BlackRock Group first reported a position in TPST in Q3 2013 and has held it in 8 quarters since. The position peaked at $216K in Q1 2016. 84 funds tracked by Wall St. Rank hold TPST as of Q4 2016.

BlackRock Group held 3 shares of Tempest Therapeutics worth $14K as of Q4 2016.
BlackRock Group left its Tempest Therapeutics share count unchanged in Q4 2016.
Tempest Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2964 holding.
BlackRock Group first reported a position in Tempest Therapeutics in Q3 2013 and has held it in 8 quarters since.
BlackRock Group's Tempest Therapeutics position peaked at $216K in Q1 2016.
84 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.